Poprawa przejść i wyników leczenia pacjentów z niewydolnością serca w domowej opiece zdrowotnej (I-TRANSFER-HF): skuteczność hybrydy typu 1 – próba wdrożeniowa
This study is trying to improve the hospital-to-home transition for people with heart failure who receive home care services. The study will test an intervention called I-TRANSFER-HF, which differs from usual care by combining early home health nurse visits and outpatient medical appointments.
The study is interested in two questions:
- Is I-TRANSFER-HF better than usual care at preventing heart failure patients from returning to the hospital within 30 days?
- Are there parts of I-TRANSFER-HF that are easy or hard to implement in the real world?
The researchers will answer these questions by testing the intervention among pairs of hospitals and home health agencies across the country. During the study, the hospital-agency pairs will be asked to implement I-TRANSFER-HF. The researchers will then compare the results from before and after I-TRANSFER-HF was adopted. They will also interview people from these hospitals and agencies to see how I-TRANSFER-HF is being implemented under real-world conditions.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
The investigators' will test two hypotheses:
Hypothesis 1 (H1): Compared to usual care, adults with heart failure who receive the I-TRANSFER-HF intervention will have fewer 30-day readmissions, ED visits, and greater days at home. The four hospital-agency pairs will all begin the study with a baseline period of no intervention and then randomly selected to start the intervention phase at different points in time. Medicare claims data from each hospital-agency pair will be used to determine outcomes, and these data will be supplemented with national claims data for external controls not in the study to test the effectiveness of the I-TRANSFER-HF intervention.
Hypothesis 2 (H2): Compared to usual care, heart failure patients who receive I-TRANSFER-HF will have a higher proportion of timely first week HHC nursing visits (within 2 days of hospital discharge, plus 2 more) and outpatient visits (within 7-days of discharge). Given the rise of telemedicine, the study will test the association between the type of outpatient visit (in-person vs. virtual), its timing, and its association with outcomes. H2 requires conducting qualitative interviews with key stakeholders across the 4 hospital-agency pairs to identify barriers and facilitators that influence I-TRANSFER-HF's implementation. The study will assess the intervention's acceptability, feasibility, fidelity, and adaptation with interviews and Medicare claims data using a multi-methods approach and guided by the updated Consolidated Framework for Implementation Research (CFIR 2.0).
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Madeline R Sterling, MD, MPH, MS
- Numer telefonu: 6469625029
- E-mail: mrs9012@med.cornell.edu
Lokalizacje studiów
-
-
New York
-
New York, New York, Stany Zjednoczone, 10021
- Rekrutacyjny
- Weill Cornell Medicine
-
Kontakt:
- Madeline R Sterling, MD, MPH, MS
- Numer telefonu: 646-962-5029
- E-mail: mrs9012@med.cornell.edu
-
Główny śledczy:
- Madeline R Sterling, MD, MPH, MS
-
New York, New York, Stany Zjednoczone, 10017
- Rekrutacyjny
- VNS Health Partners in Care
-
Kontakt:
- Kathy Bowles, PhD, RN,FAAN
- E-mail: bowles@nursing.upenn.edu
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Aim 1, Inclusion Criteria:
- Adults hospitalized for HF who transition from participating hospitals to their partner HHC agency during the study period.
Aim 1, Exclusion Criteria:
- Patients hospitalized for HF and discharged: home without HHC, or to an inpatient rehabilitation facility, skilled nursing facility, or hospice; patients with end stage renal disease on dialysis and those with left ventricular devices.
Aim 2, Inclusion Criteria:
- Healthcare professional involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.
Aim 2, Exclusion Criteria:
- Healthcare professional not involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Badania usług zdrowotnych
- Przydział: Randomizowane
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: I-TRANSFER-HF
This is a 1-year long intervention period when I-TRANSFER-HF is in operation. |
I-TRANSFER-HF is comprised of early and intensive HHC nurse visits and an outpatient visit within 7 days of discharge. Using a Hybrid Type 1, stepped wedge randomized trial design, we will test the effectiveness and implementation of I-TRANSFER-HF in partnership with 4 geographically diverse dyads of hospitals and HHC agencies ("hospital-HHC agency" dyads) across the US. |
|
Brak interwencji: Standard of Care (usual care)
This is a baseline period of usual care (UC) with no intervention. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
All-cause 30-day hospital readmission
Ramy czasowe: 30 days following post-Index HF Hospitalization
|
All-cause 30-day hospital readmission among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims |
30 days following post-Index HF Hospitalization
|
|
Number of Eligible patients
Ramy czasowe: 12 months
|
Number of heart failure patients eligible to receive I-TRANSFER-HF as assessed by Medicare claims data |
12 months
|
|
Number of Eligible Patients Who Received Protocol Components
Ramy czasowe: 12 months
|
Number of heart failure patients who received both components of I-TRANSFER-HF (front-loaded home health nurse visits and early outpatient medical follow-up), one, or none as assessed by Medicare claims data |
12 months
|
|
Modality of outpatient follow-up
Ramy czasowe: 12 months
|
The modality of outpatient follow-up received (in-person vs. virtual visit) as assessed by Medicare claims data |
12 months
|
|
Timeliness of Post-Hospital Discharge Home Health Nursing Evaluation
Ramy czasowe: 12 months
|
The timeliness of first-week nursing visits within 2 days of hospital discharge as assessed by Medicare claims data |
12 months
|
|
Timeliness of Post-Hospital Outpatient Follow-Up
Ramy czasowe: 12 months
|
The timeliness of outpatient visits within 7 days of hospital discharge as assessed by Medicare claims data |
12 months
|
|
Feasibility of implementing I-TRANSFER-HF (Qualitative Interviews)
Ramy czasowe: 30 days after intervention (year of intervention)
|
Feasibility will be assessed through qualitative interviews with site stakeholders |
30 days after intervention (year of intervention)
|
|
Feasibility of implementing I-TRANSFER-HF (Surveys)
Ramy czasowe: 30 days after intervention (year of intervention)
|
Feasibility will be measured through the completion of the validated, 4-item, Feasibility of Intervention Measure (FIM). Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). The score is calculated as the mean. The scale for this measure ranges from 4-20 with higher scores indicating greater perceived feasibility of the intervention. |
30 days after intervention (year of intervention)
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
All-cause 30-day ED visits
Ramy czasowe: 30 days following post-Index heart failure Hospitalization.
|
All-cause 30-day emergency department visits among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims data |
30 days following post-Index heart failure Hospitalization.
|
|
Days at home among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims
Ramy czasowe: During a 12-month period (year of intervention)
|
Days at home will be calculated as 365 days minus the number of inpatient days in an acute care facility, an inpatient rehabilitation facility, a skilled nursing facility, or an inpatient hospice unit. |
During a 12-month period (year of intervention)
|
|
Acceptability of I-TRANSFER-HF - Qualitative Interviews
Ramy czasowe: 30 days after intervention (year of intervention)
|
Acceptability will be assessed through qualitative interviews. |
30 days after intervention (year of intervention)
|
|
Acceptability of Intervention Measure for the I-TRANSFER-HF Study - Survey
Ramy czasowe: 30 days after intervention (year of intervention)
|
Acceptability will be assessed through the 4-item, validated, Acceptability of Intervention Measure (AIM). Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). The score is calculated as the mean. The scale for this measure ranges from 4-20 with higher scores indicating greater perceived acceptability of the intervention. |
30 days after intervention (year of intervention)
|
|
Fidelity of I-TRANSFER-HF (Participant-Completed)
Ramy czasowe: 30 days after intervention (year of intervention)
|
Fidelity will be assessed by extent to which I-TRANSFER-HF is implemented by the study site teams. Fidelity will be measured using participant-completed fidelity checklists. These checklists will be developed during the implementation process. |
30 days after intervention (year of intervention)
|
|
Fidelity of I-TRANSFER-HF (Observational Ratings)
Ramy czasowe: 30 days after intervention (year of intervention)
|
Fidelity will be assessed by extent to which I-TRANSFER-HF is implemented by the study site teams. Fidelity will be measured using observational fidelity ratings conducted by site champions. These checklists will be developed during the implementation process. |
30 days after intervention (year of intervention)
|
|
Adaptation of I-TRANSFER-HF
Ramy czasowe: 30 days after intervention (year of intervention)
|
Adaptation will be assessed with qualitative interviews to document how the intervention was modified and refined during the study period. |
30 days after intervention (year of intervention)
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Główny śledczy: Madeline R Sterling, MD, MPH, MS, Weill Medical College of Cornell University
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 23-06026204
- R01HL169312 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .